Q1 2027 Natco Pharma Ltd Earnings Call Transcript

Aug 14, 2026 / 12:00PM GMT

Release Date Price: ₹903.15 (-5.10%)

Transcript

Key Points

Positve

Consolidated PAT grew 34% quarter-on-quarter on a normalized basis, excluding a one-time tax benefit in the previous quarter.
Brazil business revenue surged 180% to INR178 crores, driven by a strong oncology pipeline.
Domestic formulation business grew to INR136 crores, with expectations of 25% volume growth for the year, supported by semaglutide and oncology.
Increased stake in Adcock Ingram to 49% strengthens strategic position in South Africa and boosts earnings contribution, with a strong flu season driving higher profits.
Crop Health Sciences business is on track to break even for the year, with a diversified portfolio of 35 products and promising pipeline.

Negative

Consolidated total revenues declined significantly to INR794.4 crores from INR1,390.6 crores year-over-year, due to lower lenalidomide revenue.
Quarter-on-quarter export sales declined by 14% in constant currency terms, attributed to seasonal order cycles.
Semaglutide brand in India is facing intense competition, with minimal profitability and uncertain pricing stability.
Crop Health Sciences business reported a loss in Q1, impacted by El Niño-related delays in the cropping season.
The proposed INR2,000 crore fundraise may lead to equity dilution, and the demerger of Crop Health Sciences is delayed by 2-3 months due to fundraising priorities.

Operator

Ladies and gentlemen, good day and welcome to the NATCO Pharma's Q1 FY 2027 earning conference call. (Operator Instructions) Ladies and gentlemen, a reminder that this call is hosted by 360 ONE Capital Markets Private Limited.

I now hand the conference over to Mr. Hrishikesh Patole from 360 ONE Capital Markets Private Limited. Thank you, and over to you, Hrishikesh.

Hrishikesh Patole;Rajeev Menon<

360 ONE Capital Markets Private Limited - Investor Relations

Thank you, Danish. Good evening, everyone. On behalf of 360 ONE, I welcome you all to the Q1 FY 2027 earnings conference call of NATCO Pharma. Hope everyone is in good health and doing well.

On behalf of NATCO today, we have with us Mr. Rajeev Nannapaneni, Vice Chairman and CEO; Mr. Amit Parekh, Chief Financial Officer; Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences; and Mr. Rajeev Menon, Investor Relations.

I now hand over the call to Rajeev Menon for the opening remarks, post which we will open the session for Q&A. Over to you, Rajeev.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.